Skip to main content

Cogenics, Epigenomics Pen Co-Marketing Pact

NEW YORK (GenomeWeb News) — Cogenics and Epigenomics have signed a co-marketing agreement for DNA methylation, Cogenics’ parent company Clinical Data said today.
Under the deal, Cogenics will promote Epigenomics' services for genome-wide DNA methylation analysis, bisulfite sequencing, and PCR, which are performed in Epigenomics’ facilities in Germany.
Also under the deal, the companies will offer regulated DNA methylation analyses in Cogenics’ US labs. Epigenomics will promote these services through its Clinical Solutions segment.  
Robert Bondaryk, senior vice president and general manager of Cogenics, said the pact expands the company’s biomarker offerings to include DNA methylation for disease diagnosis, prognosis, and drug response prediction.
Christina Dahlstroem, Clinical Solutions’ senior vice president, said the agreement will be “particularly important” to her company when pharmaceutical customers begin to use these biomarkers in clinical trials.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.